SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.
Zeinab AryanianKamran BalighiParvaneh HatamiAzadeh GoodarziNessa Aghazadeh MohandesiZeinab Mohseni AfsharPublished in: Dermatologic therapy (2022)
SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- rheumatoid arthritis
- oxidative stress
- clinical trial
- atopic dermatitis
- patient reported outcomes
- study protocol
- human health
- early onset
- coronavirus disease